Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: Aqueous dexamethasone eye drops

Journal of Pharmacy and Pharmacology

Volumn 59, Issue 5, 2007, Pages 629-635

  Loftsson, Thorsteinn ^a   Hreinsdóttir, Dagný ^a   Stefánsson, Einar ^b  

^a UNIVERSITY OF ICELAND   (Iceland)

^b LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CYCLODEXTRIN; DEXAMETHASONE; EYE DROPS; GAMMA CYCLODEXTRIN; STEROID;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SCREENING; DRUG TOLERABILITY; EYE; FEMALE; NONHUMAN; RABBIT; RETINA; VISCOSITY; VITREOUS BODY;

ADMINISTRATION, TOPICAL; ANIMALS; BETA-CYCLODEXTRINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEXAMETHASONE; DRUG DELIVERY SYSTEMS; DRUG STABILITY; DRUG STORAGE; FEMALE; GAMMA-CYCLODEXTRINS; GLUCOCORTICOIDS; METHYLATION; OPHTHALMIC SOLUTIONS; PARTICLE SIZE; RABBITS; RETINA; SOLUBILITY; SUSPENSIONS; TISSUE DISTRIBUTION;

EID: 34447334610     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.59.5.0002     Document Type: Article

References (35)

1. Beeley, N. R. F., Rossi, J. V., Mello-Filho, P. A. A., Mahmoud, M. I., Fujii, G. Y., de Juan, E., Varner, S. E. (2005) Fabrication, implantation, elution, and retrieval of a steroid-loaded polycaprolactone subretinal implant. J. Biomed. Mater. Res. A 73: 437-444
2. Degenring, R. F., Jonas, J. B. (2005) Photodynamic therapy in combination with intravitreal triamcinolone for myopic choroidal neovascularization. Acta Ophthalmol. Scand. 83: 621
3. Geroski, D. H., Edelhauser, H. F. (2001) Transsclera drug delivery for posterior segment disease. Adv. Drug Deliv. Rev. 52: 37-48
4. Hämäläinen, K. M., Kananen, K., Auriola, S., Kontturi, K., Urtti, A. (1997) Charaterization of paracellular and aqueous penetration routes in cornea conjunctiva, and slera. Invest. Ophthalmol. Vis. Sci. 38: 627-633
5. Higuchi, T., Connors, K. A. (1965) Phase-solubility techniques. Adv. Anal. Chem. Instrum. 4: 117-212
6. Hosoya, K., Lee, V. H. L., Kim, K.-J. (2005) Roles of the conjunctiva in ocular drug delivery: a review of conjunctival transport mechanisms and their regulation. Eur. J. Pharm. Biopharm. 60: 227-240
7. Jaffe, G. J., Martin, D., Callanan, D., Pearson, P. A., Levy, B., Comstock, T. (2006) Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 113: 1020-1027
8. Jonas, J. B. (2005) Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases. Acta Ophthalmol. Scand. 83: 645-663
9. Jonas, J. B., Spandau, U. H., Kamppeter, B. A., Harder, B. (2006) Follow-up after intravitreal triamcinolone acetonide for exudative age-related macular degeneration. Eye 20: 566-572
10. Loftsson, T., Hreinsdóttir, D. (2006) Determination of aqueous solubility by heating and equilibration: a technical note. AAPS PharmSciTech 7: www.aapspharmscitech.org
11. Loftsson, T., Järvinen, T. (1999) Cyclodextrins in ophthalmic drug delivery. Adv. Drug Deliv. Rev. 36: 59-79
12. Loftsson, T., Stefánsson, E. (1997) Effect of cyclodextrins on topical drug delivery to the eye. Drug Devel. Ind. Pharm. 23: 473-481
13. Loftsson, T., Stefánsson, E. (2002) Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye. Acta Ophthalmol. Scand. 80: 144-150
14. Loftsson, T., Stefánsson, E. (2007) Cyclodextrins in ocular drug delivery. J. Drug Del. Sci. Tech. 17: 3-9
15. Loftsson, T., Fridriksdottir, H., Thorisdottir, S., Stefansson, E. (1994) The effect of hydroxypropyl methylcellulose on release of dexamethasone from aqueous 2-hydroxypropyl-β-cyclodextrin formulations. Int. J. Pharm. 104: 181-184
16. Loftsson, T., Hreinsdóttir, D., Másson, M. (2005a) Evaluation of cyclodextrin solubilization of drugs. Int. J. Pharm. 302: 18-28
17. Loftsson, T., Jarho, P., Másson, M., Järvinen, T. (2005b) Cyclodextrins in drug delivery. Expert Opin. Drug Deliv. 2: 335-351
18. Loftsson, T., Konrádsdóttir, F., Másson, M. (2006a) Influence of aqueous diffusion layer on passive drug diffusion from aqueous cyclodextrin solutions through biological membranes. Pharmazie 61: 83-89
19. Loftsson, T., Sigurdsson, H. H., Hreinsdóttir, D., Konrádsdóttir, F., Stefánsson, E. (2007) Dexamethasone delivery to posterior segment of the eye. J. Incl. Phenom. Macroc. Chem. In press
20. Merkus, F. W. H. M., Verhoef, J. C., Marttin, E., Romeijn, S. G., van der Kuy, P. H. M., Hermens, W. A. J. J., Schipper, N. G. M. (1999) Cyclodextrin in nasal drug delivery. Adv. Drug Deliv. Rev. 36: 41-57
21. Myles, M. E., Neumann, D. M., Hill, J. M. (2005) Recent progress in ocular drug delivery for posterior segment disease: emphasis on transsclera iontophoresis. Adv. Drug Deliv. Rev. 57: 2063-2079
22. Nivaggioli, T., Shiah, J. G., Lin, Q. (2005) Extended release biodegradable ocular implants. US patent appl. no. 2005/0244467. Allergan Inc., US
23. Prausnitz, M. R., Noonan, J. S. (1998) Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J. Pharm. Sci. 87: 1479-1487
24. Raghava, S., Hammond, M., Kompella, U. B. (2004) Periocular routes for retinal drug delivery. Exp. Opin. Drug Deliv. 1: 99-114
25. Rudnick, D. E., Noonan, J. S., Geroski, D. H., Prausnitz, M. R., Edelhauser, H. F. (1999) The effect of intraocular pressure on human and rabbit sclera permeability. Invest. Ophthalmol. Vis. Sci. 40: 3054-3058
26. Sasaki, H., Yamamura, K., Nishida, K., Nakamura, J., Ichikawa, M. (1996) Delivery of drugs to the eye by topical application. Prog. Ret. Eye Res. 15: 583-620
27. Shell, J. W. (1982) Pharmacokinetics of topically applied ophthalmic drugs. Surv. Ophthalmol. 26: 207-218
28. Shiah, J.-G., Bhagat, R., Nivaggioli, T., Peng, L., Chou, D., Weber, D. A. (2005) Ocular implant made by a double extrusion process. US patent appl. no. 2005/0048099. Allergan Inc., USA
29. Sigurdsson, H. H., Konrádsdóttir, F., Loftsson, T., Stefánsson, E. (2007) Role of topical versus systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye. Acta Ophthalmol. Scand. In press
30. Sigurosson, H. H., Stefánsson, E., Guomundsdóttir, E., Eysteinsson, T., Thorsteinsdóttir, M., Loftsson, T. (2005) Cyclodextrin formulation of dorzolamide and its distribution in the eye after topical administration. J. Control. Release 102: 255-262
31. Slakter, J. S., Bochow, T. W., D'Amico, D. J., Marks, B., Jerdan, J., Sullivan, E. K., Robertson, S. M., Slakter, J. S., Sullins, G., Zilliox, P. (2006) Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 113: 2-13
32. Van Ooteghem, M. M. M. (1993) Formulation of ophthalmic solutions and suspensions. Problems and advantages. In: Edman, P. (ed.) Biopharmaceutics of ocular drug delivery. CRC Press, Boca Raton, pp 27-42
33. Washington, N., Washington, C., Wilson, C. G. (2001) Physiological pharmaceutics; barriers to drug absorption. 2nd edn, Taylor & Francis, London
34. Yang, T., Hussain, A., Paulson, J., Abbruscato, T. J., Ahsan, F. (2004) Cyclodextrins in nasal delivery of low-molecular-weight heparins: in vivo and in vitro studies. Pharm. Res. 21: 1127-1136
35. Yasukawa, T., Ogura, Y., Sakurai, E., Tabata, Y., Kimura, H. (2005) Intraocular sustained drug delivery using implantable polymer devices. Adv. Drug Deliv. Rev. 57: 2033-2047